Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Revenue (2018 - 2025)

Historic Revenue for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $17.2 million.

  • Arcturus Therapeutics Holdings' Revenue fell 5884.39% to $17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.6 million, marking a year-over-year decrease of 3915.17%. This contributed to the annual value of $152.3 million for FY2024, which is 868.65% down from last year.
  • According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' Revenue is $17.2 million, which was down 5884.39% from $28.3 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Revenue ranged from a high of $160.3 million in Q4 2022 and a low of $2.0 million during Q2 2021
  • For the 5-year period, Arcturus Therapeutics Holdings' Revenue averaged around $32.2 million, with its median value being $27.1 million (2022).
  • Its Revenue has fluctuated over the past 5 years, first skyrocketed by 266653.43% in 2022, then plummeted by 8075.09% in 2023.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Revenue stood at $5.8 million in 2021, then skyrocketed by 2666.53% to $160.3 million in 2022, then plummeted by 80.75% to $30.9 million in 2023, then dropped by 26.22% to $22.8 million in 2024, then fell by 24.66% to $17.2 million in 2025.
  • Its last three reported values are $17.2 million in Q3 2025, $28.3 million for Q2 2025, and $29.4 million during Q1 2025.